Navigation Links
EpiCast Report: Endometriosis - Epidemiology Forecast to 2022
Date:11/28/2013

London (PRWEB) November 28, 2013

EpiCast Report: Endometriosis - Epidemiology Forecast to 2022

Summary

Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. Globally, the disease affects up to 10% of women. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding and infertility.

The report provides an overview of the risk factors and global and historical trends for endometriosis in the 6MM. In addition, the report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15–49 years) and stages. GlobalData epidemiologists forecast that the diagnosed prevalent cases of endometriosis in the 6MM will grow from 5.66 million cases in 2012 to 5.86 million cases in 2022, at a growth rate of 3.4% over the forecast period.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of endometriosis in the 6MM, from 5.66 million prevalent cases in 2012 to 5.86 million prevalent case in 2022, at a growth rate of 3.4% over the forecast period. The US constituted the largest proportion (almost 90%) of the prevalent cases of endometriosis, with 5.24 million prevalent cases in 2022. Endometriosis is not a life-threatening condition and is largely influenced by hereditary factors. However, the condition will cause substantial economic, physical and psycho-social burden to the individual, as well as to the healthcare system, during the forecast period.

Scope

-The Endometriosis EpiCast Report provides an overview of the risk factors and global trends of endometriosis in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15–49 years) and stages.
-The endometriosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
-The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

-Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
-Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.
-Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometriosis therapeutics in each of the markets covered.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 9
3.2.1 Family history is a strong predictor for the risk of endometriosis 10
3.2.2 Late age at menarche protects women from developing endometriosis 11
3.2.3 Higher parity decreases the risk for endometriosis 12
3.3 Global Trends 13
3.3.1 US 14
3.3.2 5EU 15
3.4 Forecast Methodology 16
3.4.1 Sources Used 17
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods 20
3.5 Epidemiological Forecast of Endometriosis (2012-2022) 22
3.5.1 Diagnosed Prevalent Cases of Endometriosis 22
3.5.2 Age-Specific Prevalent Cases of Endometriosis 23
3.5.3 Age-Standardized Prevalence of Endometriosis 25
3.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage 26
3.6 Discussion 27
3.6.1 Epidemiological Forecast Insight 27
3.6.2 Limitations of the Analysis 28
3.6.3 Strengths of the Analysis 30
4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 34
4.2.1 Epidemiologists 34
4.2.2 Reviewers 34
4.2.3 Global Director of Epidemiology and Health Policy 36
4.2.4 Global Head of Healthcare 36
4.3 About GlobalData 37
4.4 About EpiCast 37
4.5 Disclaimer 37

List of Tables

Table 1: Stages of Endometriosis (as per American Society of Reproductive Medicine) 8
Table 2: Risk Factors for Endometriosis 9
Table 3: Epidemiological Sources for Diagnosed Prevalence and Stages of Endometriosis 16
Table 4: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022 22
Table 5: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, Row (%), 2012 24
Table 6: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stages, Ages 15-49 Years, N, Row (%), 2012 26

List of Figures

Figure 1: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022 23
Figure 2: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, 2012 24
Figure 3: 6MM, Age-Standardized Prevalence (%) of Diagnosed Endometriosis, Ages 15-49 Years, 2012 25
Figure 4: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stage, Ages 15-49 Years, 2012 27

Read the full report:

EpiCast Report: Endometriosis - Epidemiology Forecast to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_endometriosis_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Read the full story at http://www.prweb.com/releases/2013/11/prweb11376591.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022
2. EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022
3. Download the Merrill DataSite's Report: Best Practices of the Best Dealmakers
4. FDAnews Management Report: Managing Contract Manufacturers and Testing Labs
5. Health Care Without Harm and Physicians for Social Responsibility Report: One-Quarter of CA Hospitals Are Committed to Sustainable Food as Center of Healing Mission
6. New Report: The Online Experience of Sarcoma Patients and Supporters
7. New report: Companies created from federally funded university research fuel american innovation, economic growth
8. Report: Breast cancer incidence rates converging among white and African-American women
9. Report: Breast cancer incidence rates converging among white and African American women
10. JDCA Report: Diabetes Charity Events Promise a Cure But Don’t Deliver
11. Register to Download the Merrill DataSite's Report: Deal Drivers 2013 Half Year Report for the Americas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... ... , ... AltMed Florida , one of the fastest growing Medical Marijuana ... opening of its second MÜV™ Medical Cannabis Dispensary on the First Coast – scheduled ... Beach. , Located at Beach Plaza Shopping Center at the corner of Beach Boulevard ...
(Date:10/8/2019)... ... 2019 , ... Safe Harvest soups in glass jars launch ... Roundy’s, Smiths and Dillons. , Safe Harvest reinvented classic soup recipes to make ... fresh taste is paramount for us,” says Bryan Boches, co-founder of Safe Catch. ...
(Date:10/8/2019)... , ... October 08, 2019 , ... Dr. Amir HagShenas ... in San Jose, CA experience relief from this common and treatable condition. Dr. HagShenas’ ... to save adults from living with uncomfortable symptoms, including tender and bleeding gums, and ...
(Date:10/8/2019)... ... October 08, 2019 , ... PotentiaMetrics, an Austin, TX based ... Chief Medical Officer. Dr. Henderson will be responsible for the development and management ... served as Chair of both the Informatics Governance and the Inpatient Clinical Informatics ...
(Date:10/8/2019)... ... ... Smile Brands Inc. has been named one of the happiest companies in the ... support organization with nearly 440 affiliated practices across 18 states, has a deeply rooted ... is the latest in a series of accolades the company has received ...
Breaking Medicine News(10 mins):
(Date:10/15/2019)... , ... October 14, 2019 ... ... LP2 linearity and calibration verification kit, for Roche cobas® analyzers, Order No. ... Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and prepared ...
(Date:10/15/2019)... ... October 14, 2019 , ... An October 4 article on ... correlation between tooth loss and heart disease. The researchers found that individuals between 40 ... of also having heart-related problems, compared to just seven percent for those who never ...
(Date:10/11/2019)... ... October 11, 2019 , ... ... 13, 2019, to recognize the dedication, compassion and quality patient outcomes achieved by ... providing a unique and vital link between patients, providers and payers to improve ...
Breaking Medicine Technology: